Absolute levels of the novel anti-IL-17A antibody, secukinumab, in skin can be quantified by dermal open flow microperfusion (dOFM)

Publikation aus Health

Bruin G., Dragatin C. , Aigner B., Polus F., Calonder C., Froeliger C., Tiffner K., Bodenlenz M., Mader J., Korsatko S., Ratzer M., Pieber T. R., Loesche C., Sinner F.

Journal of Investigative Dermatology 134: S18, 2013